期刊文献+

CTRP3、TGF-β1在糖尿病肾病中的表达及相关性研究 被引量:4

Expression and correlation of CTRP3 and TGF-β1 in diabetic nephropathy
下载PDF
导出
摘要 采用免疫组织化学法检测糖尿病肾病组(DN)及正常对照组(NC)大鼠肾组织CTRP3与转化生长因子β1(TGF-β1)的表达情况。采用病例对照,研究正常健康者(NC组)、单纯2型糖尿病(T2DM组)、早期糖尿病肾病(DN1组)和临床糖尿病肾病(DN2组)患者胰岛素代谢参数、血脂和肾功能等临床指标,ELISA法检测血清CTRP3和TGF-β1水平。结果表明:DN组大鼠肾组织TGF-β1表达增高(P<0.05),CTRP3低表达(P<0.05);ELISA检测显示DN2组血清CTRP3水平显著下降(P<0.01),而TGF-β1水平显著升高(P<0.01);DN2组HOMA-IR、HbA1c、TG、ACR、BUN、SCr、Cysc水平升高(P<0.05),而GFR水平降低(P<0.01);相关分析显示血清CTRP3与TGF-β1、HOMA-IR、FBG、HbA1c、SBP、TG、ACR、SCr、BUN、Cysc呈负相关(P<0.05),与GFR呈正相关(P<0.01);回归分析显示HOMA-IR、TGF-β1、ACR、GFR是CTRP3的影响因素。这一研究提示CTRP3、TGF-β1参与DN的发展过程,与胰岛素代谢参数、血脂和肾功能相关标志物有一定的相关性。 To explore the expression of CTRP3 and TGF-β1 in renal tissue of diabetic nephropathy rats(DN)and normal control rats(NC)by immunohistochemistry.Case-control study was conducted to observe the insulin metabolic parameters,blood lipid and renal function in healthy subjects(NC group),type 2 diabetes(T2 DM group),early diabetic nephropathy(DN1 group)and clinical diabetic nephropathy(DN2 group).The serum levels of CTRP3 and TGF-β1 were detected by ELISA.The results showed that the expression of TGF-β1 was increased in DN group(P<0.05),while the expression of CTRP3 was decreased(P<0.05).ELISA showed that the level of serum CTRP3 was significantly decreased(P<0.01)while TGF-β1 was significantly increased(P<0.01);The levels of HOMA-IR,HbA1 c,TG,ACR,BUN,SCr and Cysc in DN2 group were increased(P<0.05),while GFR were decreased(P<0.01).Correlation analysis showed that serum CTRP3 was negatively correlated with TGF-β1,HOMA-IR,FBG,HbA1 c,SBP,TG,ACR,SCr,BUN,Cysc(P<0.05),and positively correlated with GFR(P<0.01).Regression analysis showed that HOMA-IR,TGF-β1,ACR and GFR were the influencing factors of CTRP3.This study suggested that CTRP3 and TGF-β1 were involved in the development of DN,related to insulin metabolism parameters,blood lipid and renal function markers.
作者 任亚丽 卢学超 解其华 王春华 魏迎凤 徐园园 REN Yali;LU Xuechao;XIE Qihua;WANG Chunhua;WEI Yingfeng;XU Yuanyuan(Nantong Health College of Jiangsu Province,Nantong 226010,China;Nantong Third People's Hospital Affiliated to Nantong University,Nantong 226000,China)
出处 《扬州大学学报(农业与生命科学版)》 CAS 北大核心 2022年第2期92-97,103,共7页 Journal of Yangzhou University:Agricultural and Life Science Edition
基金 江苏高校“青蓝工程”项目(SJS201812) 南通市卫生和计划生育委员会立项课题(MB2019024、MB2021078) 南通市科技局立项课题(JCZ20074)。
关键词 转化生长因子β1(TGF-β1) 补体C1q/肿瘤坏死因子相关蛋白3(CTRP3) 糖尿病肾病 免疫组织化学法 相关性 transforming growth factor beta 1(TGF-β1) complement C1q/tumor necrosis factor related protein 3(CTRP3) diabetic nephropathy immunohistochemistry correlation
  • 相关文献

参考文献5

二级参考文献54

  • 1SVENSSON M, SUNDKVIST G, ARNQVIST HJ, et al. Signs of nephropathy may occur early in young adults with diabetes de- spite modem diabetes managementi results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS)[J]. Diabetes Care, 2003, 26(10): 2903-2909.
  • 2KLAUS G. Renoprotection with vitamin D: specific for diabetic nephropathy[J]. Kidney Int, 2008, 73(2): 141-143.
  • 3MIETTINEN ME, KINNUNEN L, LEIVISKA J, et al. Association of serum 25-Hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: population-based cross-sectional study(FIN-D2D)[J]. PLoS One, 2014, 9(7): e100235.
  • 4DOORENBOS CR, VAN DEN BORN J, NAVIS G, et al. Possi- ble renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism[J]. Nat Rev Nephrol, 2009, 5(12): 691-700.
  • 5ISHIMURA E, NISHIZAWA Y, INABA M, et al. Serum levels of 1, 25-dihydroxyvitamin D, 24, 25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure[J]. Kidney Int, 1999, 55(3): 1019-1027.
  • 6REMUZZI G, BENIGNI A, REMUZZI A. Mechanisms of pro- gression and regression of renal lesions of chronic nephropathies and diabetes[J]. J Clin Invest, 2006, 116(2): 288-296.
  • 7EIJKELKAMP WB, ZHANG Z, REMUZZI G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoe analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial [J]. J Am Soc Nephrol, 2007, 18(5): 1540-1546.
  • 8LEVIN A, BAKRIS GL, MOLITCH M, et al. Prevalence of ab- normal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evalu- ate early kidney disease[J]. Kidney Int, 2007, 71(1): 31-38.
  • 9RAVANI P, MALBERTI F, TRIPEPI G, et al. Vitamin D levels and patient outcome in chronic kidney disease[J]. Kidney Int, 2009, 75(1): 88-95.
  • 10DE BORST MH, HAJHOSSEINY R, TAMEZ H, et al. Active vitamin D treatment for reduction of residual proteinuria: a sys- tematic review[J]. J Am Soc Nephrol, 2013, 24(11): 1863-1871.

共引文献5311

同被引文献55

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部